Novozymes is redefining hyaluronic acid (HA) with Hyasis, the next generation of high-quality HA based on the safe bacteria Bacillus subtilis, expanding the number of possible applications of HA in medical device and pharma products:
Novozymes is setting new standards for HA, by offering:
Safety – no animal-derived raw materials, organic solvents or toxins
Consistency – high batch-to-batch consistency, targeted molecular weight and narrow polydispersity
Performance – superior heat stability and up to 5 x faster dissolving time
Hyasis® Link is the new state-of-the-art proprietary crosslinking technology for modifying the properties of HA and preparing HA hydrogels, which are versatile in application and well tolerated.
Novozymes Biopharma is a world leading provider of high-quality, safe, biological based solutions used by pharma and device companies to improve quality of life.